Panel, Conference Presentation
The Cancer Diagnostics Revolution | Global Conference 2024
Milken InstituteGregory Simon, Kara Egan, Helmy Eltoukhy, Jody Hoyos, Larry Kessler, Anaeze Offodile, Greg Simon
- Liquid biopsy technology is currently utilized in 40% to 50% of stage three and four cancer patients, with predictions that it will revolutionize treatment monitoring within a decade as blood tests generate vast data including the whole proteome and metabolites.
- Blood tests are expected to detect thousands of diseases and serve as a co-pilot to primary care physicians, though their potential to replace physicians remains uncertain and the diffusion of such technology in healthcare is anticipated to be slower than natural laws suggest.
- Regulatory bodies like the US Preventive Services Task Force and the National Cancer Institute are expected to maintain conservative, mortality-based stances, with answers regarding new trial methodologies potentially taking 10 years to emerge.
- While early detection is generally viewed as critical, there is uncertainty regarding whether catching certain cancers like papillary or pancreatic cancer early will increase life expectancy due to potential lead time bias and a lack of sufficient clinical trial data.
- Teal Health plans to increase access for 20 million women overdue for cervical cancer screening and aims to secure the first Medicare-reimbursed, FDA-approved screening test for 120 million Americans within the current year.
- Significant barriers to equity include the potential for multi-cancer tests to remain inaccessible to low-income populations without policy changes, and the need to ensure community health centers deliver care comparable to academic medical centers where 80% of cancer care occurs.
- Challenges to future screening include declining provider capacity for screening conversations, insufficient time during 15-minute visits, dips in HPV vaccine uptake, and the necessity of patient navigators funded by Medicare initiatives to reach underserved communities.
- Medical guidelines and clinical practice standards are expected to be developed once more data becomes available, with a specific focus on determining the right testing protocols, follow-on activities, and cost structures.
- Advocacy strategies emphasize urging individuals to encourage loved ones to see a doctor before hospitalization is required and to ask colleagues about their screening status, alongside hopes for improved HPV vaccine uptake to prevent up to six cancer types.